recurrent ovarian cancer

Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer
Y. Watanabe, H. Nakai, H. Ueda, K. Nozaki, H. Hoshiai

International Journal of Gynecologic Cancer Feb 2005, 15 (2) 224-227; DOI: 10.1136/ijgc-00009577-200503000-00006
Weekly carboplatin and paclitaxel is safe, active, and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapy
A. Kikuchi, H. Sakamoto, T. Yamamoto

International Journal of Gynecologic Cancer Jan 2005, 15 (1) 45-49; DOI: 10.1136/ijgc-00009577-200501000-00008
Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic
M. A. Bookman

International Journal of Gynecologic Cancer Apr 2005, 15 (Suppl 1) 12-17; DOI: 10.1136/ijgc-00009577-200505001-00003
Effective weekly docetaxel for recurrent ovarian cancer: A case report
S. Komiyama, Y. Mizusawa, M. Onouchi, K. Takehara, A. Suzuki, M. Mikami

International Journal of Gynecologic Cancer Aug 2003, 13 (5) 683-686; DOI: 10.1136/ijgc-00009577-200309000-00018
Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO
Philipp Harter, Jalid Sehouli, Alexander Reuss, Annette Hasenburg, Giovanni Scambia, David Cibula, Sven Mahner, Ignace Vergote, Alexander Reinthaller, Alexander Burges, Lars Hanker, Martin Pölcher, Christian Kurzeder, Ulrich Canzler, Karl Ulrich Petry, Andreas Obermair, Edgar Petru, Barbara Schmalfeldt, Domenica Lorusso, Andreas du Bois

International Journal of Gynecologic Cancer Jan 2011, 21 (2) 289-295; DOI: 10.1097/IGC.0b013e31820aaafd
Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer
S. Ghamande, S. Lele, D. Marchetti, T. Baker, K. Odunsi

International Journal of Gynecologic Cancer Feb 2003, 13 (2) 142-147; DOI: 10.1136/ijgc-00009577-200303000-00007
Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer
M. Murakami, T. Miyamoto, T. Iida, H. Tsukada, M. Watanabe, M. Shida, H. Maeda, S. Nasu, S. Yasuda, M. Yasuda, M. Ide

International Journal of Gynecologic Cancer Jan 2006, 16 (Suppl 1) 99-107; DOI: 10.1136/ijgc-00009577-200602001-00016
High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer—A Phase 2 Cohort Study
Ilan Bruchim, Natalie Weeg, Yoav Alpert, Dana Sade, Ettie Piura, Ami Fishman

International Journal of Gynecologic Cancer May 2016, 26 (4) 640-647; DOI: 10.1097/IGC.0000000000000666
Long-Term Survival After Surgery and Radiotherapy for Recurrent or Persistent Ovarian and Tubal Cancer
Robert Rome, Joanna Dipnall, Sam Leung

International Journal of Gynecologic Cancer Jun 2018, 28 (6) 1090-1100; DOI: 10.1097/IGC.0000000000001294
Weekly Administration of Bevacizumab, Gemcitabine, and Oxaliplatin in Patients With Recurrent and Refractory Ovarian Cancer: A Preliminary Result of 19 Cases
Yuji Ikeda, Masashi Takano, Katsutoshi Oda, Hiroko Kouta, Tomoko Goto, Kazuya Kudoh, Naoki Sasaki, Tsunekazu Kita, Yoshihiro Kikuchi

International Journal of Gynecologic Cancer Feb 2013, 23 (2) 355-360; DOI: 10.1097/IGC.0b013e31827de69e

Main menu

recurrent ovarian cancer

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

recurrent ovarian cancer

Pages